RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vivoryon Therapeutics Stock

Vivoryon Therapeutics Debt 2025

Vivoryon Therapeutics Debt

-18.52 EUR

Ticker

VVY.AS

ISIN

NL00150002Q7

WKN

A2QJV6

In 2025, Vivoryon Therapeutics's total debt was -18.52 EUR, a -29.89% change from the -26.42 EUR total debt recorded in the previous year.

Vivoryon Therapeutics Aktienanalyse

What does Vivoryon Therapeutics do?

Vivoryon Therapeutics NV is a biopharmaceutical company specializing in the development of drugs for the treatment of Alzheimer's and other neurodegenerative diseases. The company was founded in 2016 in Leuven, Belgium and is headquartered in Heidelberg, Germany. Vivoryon Therapeutics has a history dating back to 2005 when it was supported by EFPIA-AIM. The company has since gone through several successful financing rounds to advance its research and development efforts. Its business model is based on the discovery and development of therapeutics with a new chemical approach to treating Alzheimer's and other neurodegenerative diseases. Vivoryon Therapeutics is currently involved in three different therapy areas: small molecule blockers, epigenetics, and big data analytics and telemetry technologies. The company is also developing a drug known as PQ912, which has the potential to slow down the progression of Alzheimer's disease. Vivoryon Therapeutics has partnerships and collaborations with various institutions to further its research and development programs. Overall, the company has the potential to revolutionize the treatment of Alzheimer's and other neurodegenerative diseases through its innovative efforts and collaborations. Vivoryon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Vivoryon Therapeutics's Debt Structure

Vivoryon Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Vivoryon Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Vivoryon Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Vivoryon Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Vivoryon Therapeutics stock

What is the debt of Vivoryon Therapeutics this year?

Vivoryon Therapeutics has a debt level of -18.52 EUR this year.

What was the debt of Vivoryon Therapeutics compared to the previous year?

The debt of Vivoryon Therapeutics has increased by -29.89% compared to the previous year dropped.

What are the consequences of high debt for investors in Vivoryon Therapeutics?

High debt can pose a risk for investors of Vivoryon Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Vivoryon Therapeutics?

Low debt means that Vivoryon Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Vivoryon Therapeutics affect the company?

An increase in debt of Vivoryon Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Vivoryon Therapeutics affect the company?

A reduction in debt of Vivoryon Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Vivoryon Therapeutics?

Some factors that can influence the debt of Vivoryon Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Vivoryon Therapeutics so important for investors?

The debts of Vivoryon Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Vivoryon Therapeutics take to change the debt?

To change the debt, Vivoryon Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Vivoryon Therapeutics pay?

Over the past 12 months, Vivoryon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vivoryon Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Vivoryon Therapeutics?

The current dividend yield of Vivoryon Therapeutics is .

When does Vivoryon Therapeutics pay dividends?

Vivoryon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vivoryon Therapeutics?

Vivoryon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Vivoryon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vivoryon Therapeutics located?

Vivoryon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vivoryon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vivoryon Therapeutics from 3/7/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 3/7/2025.

When did Vivoryon Therapeutics pay the last dividend?

The last dividend was paid out on 3/7/2025.

What was the dividend of Vivoryon Therapeutics in the year 2024?

In the year 2024, Vivoryon Therapeutics distributed 0 EUR as dividends.

In which currency does Vivoryon Therapeutics pay out the dividend?

The dividends of Vivoryon Therapeutics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vivoryon Therapeutics

Our stock analysis for Vivoryon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vivoryon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.